- Record: found
- Abstract: not found
- Article: not found
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progression on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled phase 3 trial
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.